Kyle A. Hess, Pharm.D., recognizes the clinical presentation of beta-lactam induced neurotoxicity, identifies risk factors associated with developing beta-lactam induced neurotoxicity and describes the relationship between drug levels of beta-lactams and development of neurotoxicity. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.